DAPAPHAGE-M Tablets
Composition:
DAPAPHAGE-M
- Each film coated tablet contains:
- Dapagliflozin propandiol U.S.P. equivalent to Dapagliflozin………………... 10 mg
- Metformin Hydrochloride I.P. … 500 mg (as sustained-release form)
- Excipients ……………………………………….... q.s.
- Colour – Titanium Dioxide I.P.
Description
- DAPAPHAGE-M tackles the increase in blood glucose levels not controlled by monotherapy along with providing once a day dosage convenience. DAPAPHAGE-M contains two oral anti-hyperglycaemic drugs, Metformin Sustained-release and Dapagliflozin used in the management of Type 2 Diabetes.
- Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Dapagliflozin is a Sodium glucose co-transporter 2 inhibitor which maintains blood glucose level by preventing absorption of glucose by inhibiting sodium glucose transporter 2 in proximal tubule of nephrons in kidney.
- Hence, the combination of Metformin sustained-release and Dapagliflozin complement each other and provide better glycaemic control in the management of Type 2 Diabetes and probably helps in the prevention of diabetes-associated macrovascular and microvascular complications.
Indications
- DAPAPHAGE-M is indicated as therapy when diet, exercise and monotherapy do not result in adequate glycaemic control in patients with type 2 diabetes.